テキサスにおける卵巣がんの臨床試験
テキサス内の拠点で、卵巣がんに関する122件の研究が参加者を募集しています。
テキサス内の都市
- Houston89件の研究
- San Antonio31件の研究
- Dallas28件の研究
- Austin17件の研究
- Fort Worth17件の研究
- Tyler7件の研究
- Irving5件の研究
- League City5件の研究
- Killeen4件の研究
- Abilene4件の研究
- The Woodlands4件の研究
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Hendrick Medical Center, Abilene
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Lyndon Baines Johnson General Hospital, Houston
- 他2件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- 他2件
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Texas Oncology-Austin North /ID# 279958, Austin
被験者募集中第2相
18歳以上 · 女性 · 2026/10/01更新 · NCT07024784A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- NEXT Oncology - San Antonio /ID# 278606, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07278336Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07360314First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0103 - University of Texas MD Anderson Cancer Center, Houston
- Site 0203 - Texas Oncology, Tyler
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT05128825Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Lyndon Baines Johnson General, Houston
- M D Anderson Cancer Center, Houston
被験者募集中
18歳以上 · 女性 · 2026/09/29更新 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Texas Oncology - Austin Central /ID# 275046, Austin
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
- Houston Methodist Hospital /ID# 274568, Houston
- 他3件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Total Women's Care of the Heights, Houston
- Medical Colleagues of Texas, LLP, Katy
被験者募集中観察研究
18歳以上 · 女性 · 2026/09/29更新 · NCT05051722Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Texas Oncology - DFW ( Site 8005), Fort Worth
被験者募集中第3相
18歳以上 · 女性 · 2026/09/24更新 · NCT07776691Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Texas Oncology - Abilene - Antilley Road /ID# 277739, Abilene
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735, San Antonio
- 他2件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- USO-Texas Oncology-Central/South Texas, Austin
- UT Southwestern Medical Center, Dallas
- US Oncology, The Woodlands
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT04038619A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- MD Anderson Cancer Center, Houston
- START Center for Cancer Research, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/15更新 · NCT05739981A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Texas Oncology-Austin Center, Austin
- Texas Oncology-San Antonio Medical Center Pharmacy, San Antonio
- Texas Oncology-Tyler, Tyler
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Texas Oncology-Abilene, Abilene
- Jps Health Network, Fort Worth
- The University of Texas Health Science Center Houston, Houston
- 他2件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Start Dfw, Fort Worth
- Next Oncology Dallas, Irving
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Lyndon Baines Johnson General, Houston
- Houston Methodist, Houston
- M D Anderson Cancer Center, Houston
被験者募集中第3相
18歳以上 · 女性 · 2026/09/14更新 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- UT Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 女性 · 2026/09/14更新 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- 他1件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- MD Anderson Cancer Center, Houston
- NEXT Oncology, Irving
被験者募集中第1相
18歳以上 · 女性 · 2026/09/03更新 · NCT07755436ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。